HSD17B12

Across TCGA pan-cancer cohorts, HSD17B12 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSD17B12 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HSD17B12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSD17B12 expression acts as an unfavorable survival marker.

HNSC, UCEC, and LUAD are the cancer types where HSD17B12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.698	1.000	.020	13	view →
UCEC	DFS	Quartile	All	0.813	1.000	.023	8	view →
LUAD	DFS	Median	All	0.653	0.818	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSD17B12–HNSC (DFS)

Open the HNSC breakdown →